Skip to main content
. 2020 Feb 27;8(1):e000438. doi: 10.1136/jitc-2019-000438

Figure 2.

Figure 2

Kaplan-Meier curve of PFS according to ARID1A status. (A) Among patients who received anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immunotherapy (n=375). (B) Among patients without microsatellite instability-high who received anti-PD-1/PD-L1 immunotherapy (n=359). Similar results were seen even if the MS-unknown (n=60) were excluded (p=0.02). ARID1A, AT-Rich Interactive Domain-containingprotein 1A; MS, microsatellite status; PFS, progression-free survival.